It is specifically designed to provide a range of potential benefits to the human body
GLP-1 receptor agonists have been prescribed for type 2 diabetes since the mid-2000s, giving us nearly two decades of safety data
Finally, the washed beads were resuspended in 100 L SDS loading buffer and incubated for 10 min at 70 C
It pops up in forums, gets debated in research circles, and honestly, causes a lot of confusion
| Risk Dimension | Evidence Quality | Severity if Realized | Practical Impact | |---|---|---|---| | Absorption interference (oral, same-time dosing) | Indirect/mechanistic | Moderate (reduced efficacy) | High: fixable with timing | | Direct chelation (glutathione binds alendronate) | None documented | Low | Low | | Pharmacodynamic antagonism (bone) | None documented | Potentially none or positive | Low | | Hepatic CYP interaction | Not applicable | None | None | | Renal clearance competition (IV glutathione) | Theoretical only | Unknown | Moderate precaution warranted | The dominant clinical concern is absorption interference, and it is entirely preventable with correct timing
The body makes choline itself to a limited extent